AU2013333657B2 - Compounds useful for treating ocular neovasculan - Google Patents

Compounds useful for treating ocular neovasculan Download PDF

Info

Publication number
AU2013333657B2
AU2013333657B2 AU2013333657A AU2013333657A AU2013333657B2 AU 2013333657 B2 AU2013333657 B2 AU 2013333657B2 AU 2013333657 A AU2013333657 A AU 2013333657A AU 2013333657 A AU2013333657 A AU 2013333657A AU 2013333657 B2 AU2013333657 B2 AU 2013333657B2
Authority
AU
Australia
Prior art keywords
group
substituent
alkyl
formyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013333657A
Other languages
English (en)
Other versions
AU2013333657A1 (en
Inventor
David Owen Bates
Melissa GAMMONS
Steven James Harper
Jonathan Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exonate Ltd
Original Assignee
Exonate Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218676.3A external-priority patent/GB201218676D0/en
Priority claimed from GBGB1218758.9A external-priority patent/GB201218758D0/en
Priority claimed from GB201304694A external-priority patent/GB201304694D0/en
Application filed by Exonate Ltd filed Critical Exonate Ltd
Publication of AU2013333657A1 publication Critical patent/AU2013333657A1/en
Application granted granted Critical
Publication of AU2013333657B2 publication Critical patent/AU2013333657B2/en
Assigned to EXONATE LIMITED reassignment EXONATE LIMITED Request for Assignment Assignors: THE UNIVERSITY OF BRISTOL
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013333657A 2012-10-17 2013-10-17 Compounds useful for treating ocular neovasculan Active AU2013333657B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1218676.3A GB201218676D0 (en) 2012-10-17 2012-10-17 Anti-angiogenic treatments
GB1218676.3 2012-10-17
GB1218758.9 2012-10-18
GBGB1218758.9A GB201218758D0 (en) 2012-10-18 2012-10-18 Compounds
GB1304694.1 2013-03-15
GB201304694A GB201304694D0 (en) 2013-03-15 2013-03-15 Compounds
PCT/GB2013/052716 WO2014060763A1 (en) 2012-10-17 2013-10-17 Compounds useful for treating ocular neovasculan

Publications (2)

Publication Number Publication Date
AU2013333657A1 AU2013333657A1 (en) 2015-05-28
AU2013333657B2 true AU2013333657B2 (en) 2018-04-26

Family

ID=49518992

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013333657A Active AU2013333657B2 (en) 2012-10-17 2013-10-17 Compounds useful for treating ocular neovasculan

Country Status (8)

Country Link
US (1) US10301264B2 (https=)
EP (1) EP2908811B1 (https=)
JP (2) JP2016504270A (https=)
CN (1) CN104869990B (https=)
AU (1) AU2013333657B2 (https=)
ES (1) ES2858511T3 (https=)
IN (1) IN2015DN03969A (https=)
WO (1) WO2014060763A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406956D0 (en) * 2014-04-17 2014-06-04 Univ Nottingham Compounds
GB201518365D0 (en) 2015-10-16 2015-12-02 Exonate Ltd Compounds
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
CN111448193B (zh) * 2017-09-27 2023-12-22 埃克森纳特有限公司 Srpk1抑制剂
GB202010829D0 (en) * 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases
CN113769073A (zh) * 2021-10-15 2021-12-10 杭州鑫伟低碳技术研发有限公司 一种利用生物酶治疗眼底出血的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352663A (en) * 1963-06-26 1967-11-14 Schering Ag Method of destroying a weed
EP1712242A1 (en) * 2003-12-26 2006-10-18 HAGIWARA, Masatoshi Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
WO2008080056A2 (en) * 2006-12-21 2008-07-03 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
EP2279750A1 (en) * 2008-03-25 2011-02-02 KinoPharma, Inc. Aniline derivative having anti-rna viral activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291423T1 (de) 1998-08-20 2005-04-15 Agouron Pharma Nicht-peptidische gnrh agentia, verfahren und zwischenverbindungen zur ihren herstellung
FR2840314B1 (fr) 2002-06-03 2004-08-20 Inst Francais Du Petrole Methode d'isolation thermique, procede de preparation d'un gel isolant et gel isolant obtenu
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2007072041A1 (en) * 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
US20100213228A1 (en) 2006-07-18 2010-08-26 Thule Sweden Ab System and method for providing an article organizer to a recreational vehicle
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
CN101422603A (zh) 2007-10-31 2009-05-06 马万超 不溶性生物活性蛋白质作为玻璃体内用药治疗眼科疾病
GB0803912D0 (en) 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
JP2012509306A (ja) 2008-11-22 2012-04-19 ザ ユニバーシティ オブ ブリストル ＶＥＧＦｘｘｘｂの新規な使用
WO2011036429A1 (en) 2009-09-25 2011-03-31 The University Of Bristol Detection of risk of pre-eclampsia
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
GB201009173D0 (en) 2010-05-28 2010-07-14 Univ Bristol Treatment of pain
WO2012058176A1 (en) * 2010-10-29 2012-05-03 Schering Corporation Novel heteroaryl-carboxamide derivatives as pdk1 inhibitors
GB201406956D0 (en) * 2014-04-17 2014-06-04 Univ Nottingham Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352663A (en) * 1963-06-26 1967-11-14 Schering Ag Method of destroying a weed
EP1712242A1 (en) * 2003-12-26 2006-10-18 HAGIWARA, Masatoshi Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
WO2008080056A2 (en) * 2006-12-21 2008-07-03 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
EP2279750A1 (en) * 2008-03-25 2011-02-02 KinoPharma, Inc. Aniline derivative having anti-rna viral activity

Also Published As

Publication number Publication date
US10301264B2 (en) 2019-05-28
WO2014060763A1 (en) 2014-04-24
JP2016504270A (ja) 2016-02-12
JP2018203748A (ja) 2018-12-27
EP2908811A1 (en) 2015-08-26
ES2858511T3 (es) 2021-09-30
US20150274668A1 (en) 2015-10-01
CN104869990A (zh) 2015-08-26
CN104869990B (zh) 2022-12-20
EP2908811B1 (en) 2020-12-09
IN2015DN03969A (https=) 2015-10-02
AU2013333657A1 (en) 2015-05-28
JP6738512B2 (ja) 2020-08-12

Similar Documents

Publication Publication Date Title
JP6738512B2 (ja) 眼血管形成（ｏｃｕｌａｒ ｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物
US9932330B2 (en) Piperazine derivatives for treating disorders
US10696661B2 (en) Compounds
EP4182311B1 (en) 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EXONATE LIMITED

Free format text: FORMER OWNER(S): THE UNIVERSITY OF BRISTOL